Introduction to Retatrutide
Retatrutide is an investigational therapeutic agent currently under preclinical and clinical research. It is being studied for its potential effects on various cellular pathways relevant to multiple disease models. Retatrutide is not approved by the FDA or any other regulatory agency for human use or treatment.
Mechanism of Action
Retatrutide functions by modulating specific cellular pathways that are involved in disease processes. Research is ongoing to better understand its mechanism and potential impacts on biological functions. These studies are exploratory and aim to evaluate its effects in controlled laboratory or clinical research settings only.
Key Research Areas
Retatrutide is the subject of active research and clinical trials to assess its potential in disease models such as obesity, metabolic disorders, inflammatory conditions, and certain cancers. Its safety and efficacy have not been established, and it is not currently approved for diagnosis, treatment, or prevention of any medical condition.
While preliminary research indicates retatrutide may influence specific biological targets, no conclusions about clinical benefits or risks can be made at this time. All information presented here is for scientific research purposes only and should not be interpreted as medical advice or an indication of therapeutic effectiveness. Retatrutide is not available for human use outside of regulated clinical studies.
Certificate of Analysis
| Property | Description |
| Chemical Sequence | Tyr-{Aib}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{α-Me-Leu}-Leu-Asp-Lys-{diacid-C20-gamma-Glu-(AEEA)-Lys}-Ala-Gln-{Aib}-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 (Sodium salt) |
| CAS | 2381089-83-2 |
| Molecular Formula | C223H343F3N46O70 |
| Molecular Weight | 4845.444 g/mol |
| CID | N/A |
| Appearance | White Lyophilized Powder |
Learn More About Retatrutide
- “Retatrutide, an Agonist of GIP, GLP-1, and Glucagon Receptors, Improves Markers of Pancreatic Beta-Cell Function and Insulin Sensitivity”
- “Effect of Retatrutide on Kidney Parameters in People with Type 2 Diabetes and/or Obesity—A Post-Hoc Analysis of Two Phase 2 Trials”
- “Retatrutide Showcases Historic Weight-Lowering, Glycemic Control Benefits in Phase 2 Data”
- “Triple-Hormone Combination Retatrutide Induces 24% Body Weight Loss”
- “What is Retatrutide Peptide and How Does it Work?”
